Development and Evaluation of a Digital Aftercare Program for Adolescents (12-17 Years) With Depressive Symptoms After Hospital Discharge (Mind-WIN Pilot Study) (Mind-WIN Pilot)
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jun 4, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Mind-WIN Pilot Study is exploring a new digital aftercare program designed for adolescents aged 12 to 17 who have experienced depressive symptoms after leaving the hospital. This program, which can be accessed via an app or website, offers helpful resources like videos, quizzes, and exercises focused on topics such as self-care, goal setting, and recognizing early warning signs of depression. The goal of the study is to see if this program can improve the mental health and daily functioning of young people compared to standard care.
To participate in the study, young people must have been recently discharged from a hospital after treatment for depression and have access to a smartphone or computer. They will be randomly assigned to one of three groups: one group will use the Mind-WIN program on their own, another will receive extra support through video calls while using the program, and the third group will receive regular medical care and access to the program after the study period. Researchers will evaluate whether the digital program helps improve their mental health over time. This study is not yet recruiting participants, but it aims to provide valuable insights into how technology can support young people dealing with depression.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Recently (maximum four weeks ago) discharged from (partial) inpatient treatment in one of the participating Asklepios clinics
- • Age 12 to 17 years
- * Main depressive diagnosis:
- • F32.1 Moderate depressive episode; F32.2 Major depressive episode without psychotic symptoms; F33.1 Recurrent depressive disorder, currently moderate episode; F33.2 Recurrent depressive disorder, currently severe episode without psychotic symptoms
- • Ability to give written consent or assent by persons with custody
- • Access to a smartphone, tablet or computer with internet access
- Exclusion Criteria:
- • Mental and behavioural disorders due to psychoactive substance use (ICD-10 codes F10-F19), Schizophrenia, schizotypal and delusional disorders (ICD-10 codes F20-29), major depressive episodes with psychotic symptoms (ICD-10 code F32.3), recurrent depressive disorder, current severe episode with psychotic symptoms (ICD-10 code F33.3)
- • acute suicidality
- • bipolar disorder
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Holger Schulz, Prof.
Study Director
Universitätsklinikum Hamburg-Eppendorf
Martin Schumm, Dr.
Principal Investigator
Asklepios Clinic Stadtroda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported